Literature DB >> 30145178

Anatomical changes and pathophysiology of the brain in mucopolysaccharidosis disorders.

Brian W Bigger1, David J Begley2, Daniela Virgintino3, Alexey V Pshezhetsky4.   

Abstract

Mucopolysaccharidosis (MPS) disorders are caused by deficiencies in lysosomal enzymes, leading to impaired glycosaminoglycan (GAG) degradation. The resulting GAG accumulation in cells and connective tissues ultimately results in widespread tissue and organ dysfunction. The seven MPS types currently described are heterogeneous and progressive disorders, with somatic and neurological manifestations depending on the type of accumulating GAG. Heparan sulfate (HS) is one of the GAGs stored in patients with MPS I, II, and VII and the main GAG stored in patients with MPS III. These disorders are associated with significant central nervous system (CNS) abnormalities that can manifest as impaired cognition, hyperactive and/or aggressive behavior, epilepsy, hydrocephalus, and sleeping problems. This review discusses the anatomical and pathophysiological CNS changes accompanying HS accumulation as well as the mechanisms believed to cause CNS abnormalities in MPS patients. The content of this review is based on presentations and discussions on these topics during a meeting on the brain in MPS attended by an international group of MPS experts.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gangliosides; Heparan sulfate proteoglycans; Mucopolysaccharidosis; Neuropathology

Mesh:

Substances:

Year:  2018        PMID: 30145178     DOI: 10.1016/j.ymgme.2018.08.003

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  29 in total

1.  Quantitative brain MRI morphology in severe and attenuated forms of mucopolysaccharidosis type I.

Authors:  Victor Kovac; Elsa G Shapiro; Kyle D Rudser; Bryon A Mueller; Julie B Eisengart; Kathleen A Delaney; Alia Ahmed; Kelly E King; Brianna D Yund; Morton J Cowan; Julian Raiman; Eva G Mamak; Paul R Harmatz; Suma P Shankar; Nadia Ali; Stephanie R Cagle; Jeffrey R Wozniak; Kelvin O Lim; Paul J Orchard; Chester B Whitley; Igor Nestrasil
Journal:  Mol Genet Metab       Date:  2022-01-07       Impact factor: 4.797

Review 2.  The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy.

Authors:  Anna-Maria Wiesinger; Brian Bigger; Roberto Giugliani; Maurizio Scarpa; Tobias Moser; Christina Lampe; Christoph Kampmann; Florian B Lagler
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

3.  Convergent molecular mechanisms underlying cognitive impairment in mucopolysaccharidosis type II.

Authors:  Thiago Corrêa; Fabiano Poswar; Cíntia B Santos-Rebouças
Journal:  Metab Brain Dis       Date:  2021-11-19       Impact factor: 3.655

4.  Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I, a randomized, open-label, controlled pilot study.

Authors:  Agnes H Chen; Paul Harmatz; Igor Nestrasil; Julie B Eisengart; Kelly E King; Kyle Rudser; Alexander M Kaizer; Alena Svatkova; Amy Wakumoto; Steven Q Le; Jacqueline Madden; Sarah Young; Haoyue Zhang; Lynda E Polgreen; Patricia I Dickson
Journal:  Mol Genet Metab       Date:  2019-11-30       Impact factor: 4.797

5.  Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.

Authors:  Hideto Morimoto; Sachiho Kida; Eiji Yoden; Masafumi Kinoshita; Noboru Tanaka; Ryuji Yamamoto; Yuri Koshimura; Haruna Takagi; Kenichi Takahashi; Tohru Hirato; Kohtaro Minami; Hiroyuki Sonoda
Journal:  Mol Ther       Date:  2021-01-26       Impact factor: 11.454

6.  AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice.

Authors:  Jiaming Wang; Yue Zhang; Craig A Mendonca; Onur Yukselen; Khaja Muneeruddin; Lingzhi Ren; Jialing Liang; Chen Zhou; Jun Xie; Jia Li; Zhong Jiang; Alper Kucukural; Scott A Shaffer; Guangping Gao; Dan Wang
Journal:  Nature       Date:  2022-03-23       Impact factor: 69.504

7.  Transcriptomic Changes Related to Cellular Processes with Particular Emphasis on Cell Activation in Lysosomal Storage Diseases from the Group of Mucopolysaccharidoses.

Authors:  Estera Rintz; Lidia Gaffke; Magdalena Podlacha; Joanna Brokowska; Zuzanna Cyske; Grzegorz Węgrzyn; Karolina Pierzynowska
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

8.  Temporospatial Development of Neuropathologic Findings in a Canine Model of Mucopolysaccharidosis IIIB.

Authors:  Tyler A Harm; Shannon J Hostetter; Ariel S Nenninger; Bethann N Valentine; N Matthew Ellinwood; Jodi D Smith
Journal:  Vet Pathol       Date:  2020-11-18       Impact factor: 2.221

9.  Targeted Metabolomic Analysis of a Mucopolysaccharidosis IIIB Mouse Model Reveals an Imbalance of Branched-Chain Amino Acid and Fatty Acid Metabolism.

Authors:  Valeria De Pasquale; Marianna Caterino; Michele Costanzo; Roberta Fedele; Margherita Ruoppolo; Luigi Michele Pavone
Journal:  Int J Mol Sci       Date:  2020-06-12       Impact factor: 5.923

10.  Critical clinical situations in adult patients with Mucopolysaccharidoses (MPS).

Authors:  Karolina M Stepien; Anait K Gevorkyan; Christian J Hendriksz; Tinatin V Lobzhanidze; Jordi Pérez-López; Govind Tol; Mireia Del Toro Riera; Nato D Vashakmadze; Christina Lampe
Journal:  Orphanet J Rare Dis       Date:  2020-05-14       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.